Showing results (391-400 of 646) with videos related to
Sort By:
Pageof 65
Journal of the American Heart Association|June 16, 2017
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF TrialGeorge C Leef, Anne S Hellkamp, Manesh R Patel, et al.Lancet (London, England)|March 10, 2015
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)Jeffrey B Washam, Susanna R Stevens, Yuliya Lokhnygina, et al.Circulation. Cardiovascular Imaging|February 5, 2019
Predictive Model for High-Risk Coronary Artery DiseaseJames J Jang, Manjushri Bhapkar, Adrian Coles, et al.The American Journal of Cardiology|September 10, 2017
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Sean T Chen, Anne S Hellkamp, Richard C Becker, et al.American Heart Journal|May 30, 2021
The association of healthcare disparities and patient-specific factors on clinical outcomes in peripheral artery diseaseDennis I Narcisse, Cassie B Ford, E Hope Weissler, et al.European Heart Journal|April 14, 2017
Infarct size, left ventricular function, and prognosis in women compared to men after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: results from an individual patient-level pooled analysis of 10 randomized trialsIoanna Kosmidou, Björn Redfors, Harry P Selker, et al.PLOS Digital Health|May 29, 2024
Frameworks for procurement, integration, monitoring, and evaluation of artificial intelligence tools in clinical settings: A systematic reviewSarim Dawar Khan, Zahra Hoodbhoy, Mohummad Hassan Raza Raja, et al.Journal of the American Heart Association|May 31, 2021
Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLIDMarc D Samsky, Anne Hellkamp, William R Hiatt, et al.Vascular Medicine (London, England)|June 4, 2021
Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y12 inhibitors: Insights from the EUCLID trialJudith Hsia, Sarah T Kavanagh, Charles W Hopley, et al.The American Journal of Cardiology|June 25, 2017
Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial)Jeffrey B Washam, Anne S Hellkamp, Yuliya Lokhnygina, et al.Pageof 65